Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorReuben, S-
dc.contributorMathai, A-
dc.contributorSumi, MG-
dc.contributorNair, MD-
dc.contributorRadhakrishnan, VV-
dc.identifier.citationINDIAN JOURNAL OF MEDICAL RESEARCH. 113; ; 234-238en_US
dc.description.abstractBackground & objectives: The precise etiological factors in Guillain-Barre syndrome (GBS) are still unknown. However, humoral and cellular immune factors may have a role in the pathogenesis of GBS. The present study was undertaken to evaluate the clinical significance of circulating serum IgG antibody to GD1b ganglioside in patients with GBS.Methods: Serial samples of serum were collected from 18 patients with GBS undergoing plasma exchange (PE) during their hospital stay. Serum IgG antibody titers to GD1b, before, during as well as following PE were measured by an indirect enzyme-linked immunosorbent assay (ELISA).Results: In 10 of 18 patients with GBS the antibody to GD1b was present in high titers (1:640-1:5120) prior to PE and the antibody titers in these 10 patients decreased following PE. At the time of completion of the study, the anti GD1b antibody titers declined in relation to clinical recovery in 7 of 10 patients with GBS.Interpretation & conclusion: The findings of the present study show that antibody to GD1b gangliosides may be one of the immunological factors in the pathogenesis of GBS land PE decreases the anti GD1b antibody titers in these patients.-
dc.titleSignificance of serum antibody to GD1b ganglioside in patients with Guillain-Barre syndrome-
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.